We're building a better ClinicalTrials.gov. Check it out and tell us what you think!
ClinicalTrials.gov Menu

Pharmacokinetics and Safety Study of Single and Multiple Oral Doses Prodarsan™ in Patients With Cockayne Syndrome

The safety and scientific validity of this study is the responsibility of the study sponsor and investigators. Listing a study does not mean it has been evaluated by the U.S. Federal Government. Read our disclaimer for details.
ClinicalTrials.gov Identifier: NCT01142154
Recruitment Status : Completed
First Posted : June 11, 2010
Last Update Posted : June 23, 2011
Information provided by:
DNage B.V.

Brief Summary:
This study is to compare the exposure of orally administered Prodarsan to the intravenous dosed Osmitrol (10% solution) in Cockayne Syndrome (CS) patients. Also the pharmacokinetics of single and multiple orally dosed Prodarsan will be evaluated and compared to intravenous dose of Osmitrol in CS patients.

Condition or disease Intervention/treatment Phase
Cockayne Syndrome Drug: Prodarsan Phase 1 Phase 2

Layout table for study information
Study Type : Interventional  (Clinical Trial)
Actual Enrollment : 5 participants
Allocation: Non-Randomized
Intervention Model: Single Group Assignment
Masking: None (Open Label)
Official Title: A Phase I/II Crossover Study To Evaluate and Compare the Pharmacokinetics of a Single IV Dose of D-Mannitol (Osmitrol®10%) to Single and Multiple, Escalating Doses of Liquid, Oral Prodarsan™ in Patients With Cockayne Syndrome
Study Start Date : June 2010
Actual Primary Completion Date : September 2010
Actual Study Completion Date : February 2011

Resource links provided by the National Library of Medicine

Arm Intervention/treatment
Experimental: oral, liquid solution Drug: Prodarsan
Prodarsan TID, oral solution, 6-8 days

Primary Outcome Measures :
  1. Evaluate and compare the pharmacokinetics of D-mannitol following a single IV dose of Osmitrol to single and multiple oral doses of Prodarsan in pediatric patients with Cockayne Syndrome [ Time Frame: 6 months ]

Secondary Outcome Measures :
  1. Evaluate the safety and tolerability of administering oral Prodarsan in CS patients over a six (6) to eight (8) day period, including dose escalation to reach a Target Dose [ Time Frame: 6 months ]

Information from the National Library of Medicine

Choosing to participate in a study is an important personal decision. Talk with your doctor and family members or friends about deciding to join a study. To learn more about this study, you or your doctor may contact the study research staff using the contacts provided below. For general information, Learn About Clinical Studies.

Layout table for eligibility information
Ages Eligible for Study:   2 Years to 10 Years   (Child)
Sexes Eligible for Study:   All
Accepts Healthy Volunteers:   No

Inclusion Criteria:

  • Parents or legal guardian(s) of the pediatric patient with CS must be willing and able to give written Informed Consent. Informed Assent will be offered to children who can understand and participate in the Informed Assent process.
  • Diagnosis of CS confirmed by one of the following laboratory diagnostic test results:

    • Demonstration by molecular diagnostic analyses of two mutations in either the ERCC6 gene or the ERCC8 gene, wherein both mutations are either known to be pathogenic or are obviously detrimental (including nonsense or frameshift mutations, mutations of "invariant" splice site consensus signals, or large deletions/rearrangements); OR
    • A pattern of DNA repair responses in patient's cultured skin fibroblast cells indicative of a specific deficiency of transcription-coupled DNA nucleotide excision repair after irradiation with ultraviolet light, namely a significant deficiency of cellular survival (and/or "recovery of ribonucleic acid [RNA] synthesis," if that has been specifically measured) coupled with a normal test for "unscheduled DNA synthesis" OR
    • Decreased cell survival and/or "recovery of RNA synthesis" in UV-irradiated patient's skin fibroblast cultures and rescue of these parameters by fusion to reference cell lines with known NER defects (functional complementation analysis) OR
    • Quantitative RT-PCR to quantify mRNA levels of CS-A and CS-B transcripts.
  • Weight inclusive of 10 kg to 25 kg.
  • Male or female, inclusive of two (2) to ten (10) years of age.
  • Clinically acceptable hematocrit as judged by the Principal Investigator (PI).
  • The investigator has the opinion that the patient and caregiver are willing and able to comply with protocol requirements.

Exclusion Criteria:

  • Any concurrent illness (other than related to CS), disability or clinically significant abnormality, including laboratory tests, that may affect the interpretation of the PK or safety data or prevent the patient from safely completing the assessments required by the protocol as judged by the investigator. Such conditions include, but are not limited to:

    • Ascites or generalized edema.
    • Nephrotic syndrome or history of abnormal kidney function.
    • Clinically significant thyrotoxicosis.
    • Known history of hyperprolinemia.
    • Clinically significant dehydration as judged by the investigator
  • Severely compromised venous access.
  • Presence of an external ventricular, abdominal, or chest drain.
  • Subjects due to receive radioiodine therapy, two (2) weeks before or two (2) weeks following the study period.
  • Participation in another PK or treatment clinical study within thirty (30) days prior to signing and dating of Informed Consent/Assent Form for this study.
  • As judged by the investigator, clinical features present at the time of initial screening, that are associated with the terminal phases of the natural progression of CS, indicating that safe travel and completion of the study and its assessments are unlikely, including any of the following:

    • Continuous or intermittent dependence on supplemental oxygen at home during the six (6) months prior to enrollment in this study; OR
    • Two or more hospitalizations due to pneumonia, during the twelve (12) months prior to enrollment in this study; OR
    • A documented, net weight loss of at least 10%, which has not been recovered, and which includes a significant net weight loss (beyond the estimated error of the measurement) over the most recent 6 months despite intensive nutritional support including the use of gastrostomy tube feedings.
  • Known hypersensitivity to any of the components found in Prodarsan, D-mannitol, iohexol or iodine compounds.
  • History of clinically significant drug sensitivity or allergic reaction such as anaphylaxis.

Information from the National Library of Medicine

To learn more about this study, you or your doctor may contact the study research staff using the contact information provided by the sponsor.

Please refer to this study by its ClinicalTrials.gov identifier (NCT number): NCT01142154

Layout table for location information
United States, Massachusetts
Children's Hospital Boston
Boston, Massachusetts, United States, 02115
Sponsors and Collaborators
DNage B.V.
Layout table for investigator information
Principal Investigator: Edward Neilan, MD Boston Children's Hospital
Layout table for additonal information
Responsible Party: Lia Dam/Director Clinical Operations, DNage
ClinicalTrials.gov Identifier: NCT01142154    
Other Study ID Numbers: MP1104-02
First Posted: June 11, 2010    Key Record Dates
Last Update Posted: June 23, 2011
Last Verified: June 2011
Keywords provided by DNage B.V.:
Cockayne Syndrome
Genetic disease, inborn
DNA Repair-Deficiency Disorders
Additional relevant MeSH terms:
Layout table for MeSH terms
Cockayne Syndrome
Pathologic Processes
Bone Diseases, Developmental
Bone Diseases
Musculoskeletal Diseases
Heredodegenerative Disorders, Nervous System
Neurodegenerative Diseases
Nervous System Diseases
Abnormalities, Multiple
Congenital Abnormalities
Genetic Diseases, Inborn
DNA Repair-Deficiency Disorders
Metabolic Diseases